



## Non-Intensive Therapies for AML: Emerging Strategies and Evolving Therapies for Complex Patients

### References

1. Waclawiczek A, Leppä AM, Renders S, et al. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax. *Cancer Discov.* 2023 Jun 2;13(6):1408-1427. doi: 10.1158/2159-8290.CD-22-0939. PMID: 36892565; PMCID: PMC10236156.
2. Maiti A, DiNardo CD, Daver NG, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. *Blood Cancer J.* 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w. PMID: 33563904; PMCID: PMC7873265.
3. Short NJ, Daver N, Dinardo CD, et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. *J Clin Oncol.* 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26. PMID: 38277619; PMCID: PMC11095865.
4. Willekens C, Chraïbi S, Decroocq J, et al. Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia. *Blood* 2022;140 (Suppl1): 537-538. doi: <https://doi.org/10.1182/blood-2022-165464>
5. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. *N Engl J Med.* 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. PMID: 32786187.
6. Liu QS, Welkie RL, Huang Y, et al. Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF). *Blood* 2023;142 (Suppl1): 5933. doi: <https://doi.org/10.1182/blood-2023-179609>
7. Yilmaz, M, Alfayez, M, DiNardo, CD, et al. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *J Hematol Oncol.* 2020;13:132. <https://doi.org/10.1186/s13045-020-00964-5>
8. Kennedy, VE, Smith, CC. FLT3 targeting in the modern era: from clonal selection to combination therapies. *Int J Hematol.* 2024;120:528-540. <https://doi.org/10.1007/s12185-023-03681-0>
9. Candoni A, Coppola G. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia. *Hematol Rep.* 2024 Apr 18;16(2):244-254. doi: 10.3390/hematolrep16020024. PMID: 38651453; PMCID: PMC11036224.
10. Subklewe M, Bücklein V, Sallman D, Daver N. Novel immunotherapies in the treatment of AML: is there hope? *Hematology Am Soc Hematol Educ Program.* 2023;2023(1):691-701. doi: <https://doi.org/10.1182/hematology.2023000455>
11. Wang ES, Baron J. Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop. *Hematology Am Soc Hematol Educ Program* 2020; 2020(1): 57-66. doi: <https://doi.org/10.1182/hematology.2020000089>
12. Sahasrabudhe KD, Mims AS. Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3. *Hematology Am Soc Hematol Educ Program* 2022; 2022(1):15-22. doi: <https://doi.org/10.1182/hematology.2022000325>
13. Yang H, Xun Y, You H. The landscape overview of CD47-based immunotherapy for hematological malignancies. *Biomark Res.* 2023;11:15. <https://doi.org/10.1186/s40364-023-00456-x>



14. Daver NG, Vyas P, Kambhampati S, et al. Tolerability and Efficacy of the Anticlust of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. *J Clin Oncol*. 2023 Nov 1;41(31):4893-4904. doi: 10.1200/JCO.22.02604. Epub 2023 Sep 13. PMID: 37703506; PMCID: PMC10617926.
15. Gilead Statement on Discontinuation of Phase 3 ENHANCE-3 Study in AML. February 7, 2024. Accessed June 7, 2024 at: <https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml>
16. Daver N, Stein AS, Bixby D, et al. Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). *Blood* 2023;142 (Suppl1): 4278. doi: <https://doi.org/10.1182/blood-2023-173991>
17. Kubicka E, Lum LG, Huang M, Thakur A. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia. *Front Immunol*. 2022 Nov 1;13:899468. doi: 10.3389/fimmu.2022.899468. PMID: 36389764; PMCID: PMC9663847.
18. Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. *Blood*. 2018;131 (1):30-38. doi: <https://doi.org/10.1182/blood-2017-06-741058>
19. Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. *Curr Hematol Malig Rep*. 2018 Dec;13(6):417-425. doi: 10.1007/s11899-018-0472-8. PMID: 30280288; PMCID: PMC6295344.
20. Clark MC, Stein A. CD33 directed bispecific antibodies in acute myeloid leukemia. *Best Practice & Research Clinical Haematology*. 2020.33(4):101224. ISSN 1521-6926. <https://doi.org/10.1016/j.beha.2020.101224>.
21. Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. *Blood*. 2021 Feb 11;137(6):751-762. doi: 10.1182/blood.2020007732. PMID: 32929488; PMCID: PMC7885824.
22. Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. *Leukemia*. 2021 Jul;35(7):1843-1863. doi: 10.1038/s41375-021-01253-x. Epub 2021 May 5. PMID: 33953290; PMCID: PMC8257483.
23. Wong KK, Hassan R, Yaacob NS. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *Front Oncol*. 2021 Feb 25;11:624742. doi: 10.3389/fonc.2021.624742. PMID: 33718188; PMCID: PMC7947882.
24. Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. *Curr Hematol Malig Rep*. 2018;13:417-425. <https://doi.org/10.1007/s11899-018-0472-8>
25. Uy GL. Turning AML targets inside out. *Blood*. 2021;138 (25): 2598-2599. doi: <https://doi.org/10.1182/blood.2021013241>
26. Damiani D, Tiribelli M. CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand? *Biomedicines*. 2024 May 28;12(6):1194. doi: 10.3390/biomedicines12061194. PMID: 38927401; PMCID: PMC11200794.
27. Saito S, Nakazawa Y. CAR-T cell therapy in AML: recent progress and future perspectives. *Int J Hematol*. 2024;120:455-466. <https://doi.org/10.1007/s12185-024-03809-w>
28. Guo S, Gao X, Sadhana, M. et al. Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia. *Curr Treat Options in Oncol*. 2023;24:1614-1632. <https://doi.org/10.1007/s11864-023-01140-w>



29. Halpern AB, Walter RB. Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. *Hematology Am Soc Hematol Educ Program* 2020; 2020(1):129-134. doi: <https://doi.org/10.1182/hematology.2020000097>
30. Jillella AP, Cortes JE, Kota VK. Optimizing management of acute leukemia in community centers and when to refer. *Hematology Am Soc Hematol Educ Program* 2020; 2020(1): 123-128. doi: <https://doi.org/10.1182/hematology.2020000096>
31. Lantz J, Pham N, Jones C, et al. Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting. *Blood*. 2023;142 (Suppl1):7436. doi: <https://doi.org/10.1182/blood-2023-190176>

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Pfizer, Inc.